Marnetegragene autotemcel

Drug Overview

In the highly specialized field of hematology, the ability to treat rare, life-threatening immune disorders has reached a new frontier. Marnetegregene autotemcel is a groundbreaking medication within the Gene Therapy drug class. It is designed to treat children suffering from severe Leukocyte Adhesion Deficiency-I (LAD-I), a devastating genetic condition that severely impairs the immune system and makes infants and young children highly vulnerable to recurrent, fatal infections.

As an advanced, customized Biologic medication, this therapy utilizes the patient’s own blood-forming stem cells to correct the disease at its genetic root. By offering a one-time treatment that addresses the underlying defect, it provides families with new hope, transforming a previously fatal diagnosis into a manageable and potentially curable condition.

• Generic Name: marnetegragene autotemcel
• US Brand Names: Kresladi
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: FDA-approved (March 2026) under the accelerated approval pathway for the treatment of pediatric patients with severe LAD-I.

What Is It and How Does It Work? (Mechanism of Action)

To understand how marnetegragene autotemcel works, we must first understand the condition it treats. In severe LAD-I, a genetic mutation in the ITGB2 gene prevents the body from producing a vital protein called CD18. Normally, CD18 acts like Velcro on the surface of white blood cells (neutrophils), allowing them to stick to blood vessel walls and exit into tissues to fight off bacterial and fungal infections. Without CD18, white blood cells remain trapped in the bloodstream, leaving the skin, mucous membranes, and internal organs completely defenseless against infection.

Marnetegregene autotemcel serves as a highly precise Targeted Therapy to fix this broken system at the molecular and hematological level. The mechanism of action is an ex vivo (outside the body) gene modification process:

1. Cell Collection: The patient’s own blood-forming stem cells (CD34+ cells) are collected from their blood.
2. Viral Vector Delivery: In a specialized laboratory, a harmless, modified virus (a lentiviral vector) is used to insert a working, functional copy of the ITGB2 gene directly into the DNA of the patient’s stem cells.
3. Infusion and Engraftment: The patient receives chemotherapy to clear out their diseased bone marrow. The genetically corrected cells are then infused back into their bloodstream.
4. Restoring Immune Function: These new cells travel to the bone marrow and begin producing healthy white blood cells that naturally express the missing CD18 and CD11a proteins. This restores leukocyte adhesion, allowing the immune system to successfully locate and destroy invading pathogens.

FDA-Approved Clinical Indications

Primary Indication

In the hematology drug category, marnetegragene autotemcel is specifically indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) caused by biallelic variants in the ITGB2 gene. This therapy is specifically approved for patients who do not have an available human leukocyte antigen (HLA)-matched sibling donor to provide a traditional allogeneic stem cell transplant.

Other Approved & Off-Label Uses

Because this medication is a highly personalized, autologous product manufactured from a patient’s own unique cells, its use is strictly limited to its primary approved indication.

• There are no other approved blood, bone marrow, lymphatic system, or oncological uses for marnetegragene autotemcel.
• There are no recognized off-label uses due to the extreme specificity and intensive safety monitoring required for this complex genetic therapy.

Dosage and Administration Protocols

Marnetegragene autotemcel is a custom-made, single-dose therapy. The final dosage depends on the number of viable, genetically modified stem cells successfully manufactured from the patient’s initial cell collection.

Important Adjustments:

• Manufacturing Failure: Because the drug is made from living cells, manufacturing is not always successful. If the minimum dose is not achieved, patients may require a second stem cell collection.
• Renal/Hepatic Insufficiency: The stem cell product itself does not require organ-based dose adjustments. However, the heavy “conditioning” chemotherapy required before the cell infusion is highly toxic. Patients with severe kidney or liver impairment may require major chemotherapy adjustments or may be ineligible for the procedure.
• Infusion Rates: The medication is infused at a controlled rate while monitoring for severe hypersensitivity reactions to the cell preservative (DMSO).

Clinical Efficacy and Research Results

Clinical study data leading up to its 2026 accelerated approval highlights life-changing efficacy for children with severe LAD-I. The approval was largely based on a Phase 1/2 clinical trial involving nine pediatric patients.

Data demonstrated that following the infusion of marnetegragene autotemcel, all patients achieved significant increases in neutrophil CD18 and CD11a surface expression by month 12, which successfully sustained through month 24. Prior to treatment, these children suffered from severe, life-threatening infections and high early-childhood mortality rates. Post-treatment, the restoration of these vital immune biomarkers drastically reduced the incidence of serious infections, allowing the children to safely participate in day-to-day activities with a vastly improved quality of life.

Safety Profile and Side Effects

Black Box Warning

WARNING: HEMATOLOGIC MALIGNANCIES AND SEVERE INFECTIONS

Patients treated with marnetegragene autotemcel are at risk of developing hematologic malignancies (blood cancers) due to the insertional nature of viral gene therapies. Patients must undergo clinical monitoring and complete blood counts at least annually for a minimum of 15 years to check for signs of leukemia. Additionally, the required chemotherapy conditioning causes severe immune suppression, leading to a high risk of life-threatening or fatal infections before the new stem cells engraft.

Common side effects (>10%)

• Mucositis (severe mouth sores from the chemotherapy)
• Decreased blood counts (low red blood cells, white blood cells, and platelets)
• Febrile neutropenia (fever accompanying low white blood cells)
• Upper respiratory and viral infections
• Elevated liver enzymes
• Nausea, vomiting, and skin rashes

Serious adverse events

• Hematologic malignancy (blood cancer)
• Neutrophil engraftment failure (the bone marrow fails to produce new, healthy white blood cells by Day 43 post-infusion)
• Severe hypersensitivity or anaphylaxis related to dimethyl sulfoxide (DMSO), the preservative used in the cell suspension

Management Strategies

If a patient develops a fever during the neutropenic recovery phase, immediate hospitalization and broad-spectrum intravenous antibiotics are mandatory. To manage delayed platelet and red blood cell recovery, patients will rely on carefully matched blood and platelet transfusions. Hypersensitivity reactions during infusion are managed by slowing the infusion rate and administering antihistamines and corticosteroids.

Research Areas

Current research and active clinical trials in the field of gene therapy are focusing on long-term safety tracking. The FDA requires a post-marketing registry to follow treated patients for 15 years to confirm long-term clinical benefits and monitor for delayed cancer risks. Furthermore, researchers are actively investigating gentler, targeted conditioning regimens—such as antibody-based bone marrow clearing—to replace the highly toxic chemotherapy currently used, which would drastically reduce the short-term risks of this otherwise transformative therapy.

Disclaimer: The research mentioned regarding “antibody-based bone marrow clearing” (using targeted biologics like anti-CD117) to replace busulfan is an active and foundational area of hematology research in 2026. While busulfan remains the current standard for “conditioning” the marrow before Kresladi infusion, these targeted antibody approaches represent the next frontier in making gene therapy safer for fragile pediatric patients.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Genetic Testing: To confirm biallelic variants in the ITGB2 gene.
• HLA Typing: To confirm the patient lacks a fully matched sibling donor.
• Complete Blood Count (CBC) and Organ Function: Baseline heart, lung, kidney, and liver testing to ensure the child can tolerate myeloablative chemotherapy.
• Disease Screening: Screening for active HIV, Hepatitis B, and Hepatitis C.

Precautions during treatment

• Strict Infection Control: Patients must remain in a highly sterilized, isolated hospital environment during the chemotherapy and cell recovery process.
• Transfusion Triggers: Medical teams will set strict transfusion thresholds (e.g., hemoglobin below 7 g/dL or platelets below 10,000 cells/microliter) to prevent spontaneous bleeding and severe anemia.
• Medication Restrictions: Antiretroviral medications (used for HIV) must be stopped at least one month prior to stem cell collection, as they can interfere with the viral vector manufacturing process.

“Do’s and Don’ts” List

• DO ensure all standard childhood vaccinations are given before starting the conditioning process, as live vaccines are not recommended after treatment.
• DO discuss fertility preservation options with your medical team before treatment begins, as the pre-treatment chemotherapy can cause permanent infertility.
• DO commit to annual blood tests for the next 15 years to monitor your child’s long-term safety and cancer risk.
• DON’T allow the patient to donate blood, organs, tissues, or cells at any point in their life after receiving this gene therapy.
• DON’T administer live viral vaccines during or immediately following treatment until hematological recovery is fully confirmed by the medical team.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. Gene therapy carries significant risks, and only a specialized hematology and transplant team can determine if this treatment is safe and appropriate for your child’s specific medical condition.